Neuronetics, Inc. (NASDAQ:STIM) is set to announce third quarter earning results on Monday 2nd November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, STIM to report 3Q20 loss of $ 0.28 per share.
For the full year, analysts anticipate top line of $ 45.90 million, while looking forward to loss of $ 1.55 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 69.00 million ~ $ 71.00 million
Click Here For More Historical Outlooks Of Neuronetics, Inc.
Previous Quarter Performance
Neuronetics, Inc. outlined loss for the second quarter of $ 0.41 per share, from the revenue of $ 9.74 million. The quarterly revenues declined 41.22 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.51 per share from $ 8.20 million in revenue. The bottom line results beat street analysts by $ 0.1 or 19.61 percent, at the same time, top line results outshined analysts by $ 1.54 million or 18.78 percent.
Stock Performance
On Friday, shares of Neuronetics, Inc. has traded high as $ 5.30 and has cracked $ 4.87 on the downward trend, reaching $ 4.95 with volume of 196.60 thousand shares.
According to the previous trading day, closing price of $ 4.95, representing a 324.80 % increase from the 52 week low of $ 1.25 and a 41.52 % decrease over the 52 week high of $ 9.08.
The company has a market capital of $ 93.37 million and is part of the Healthcare sector and Diagnostics & Research industry.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
